Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | FOS | P01100 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18182094 | 0.88 | CSNK2A1 (0.44) | CSNK2A1PNMTHCRTR1HCRTR2CTSL | |
| SCHEMBL20061669 | 0.83 | PDE2A (0.44) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL16913143 | 0.81 | P2RX3 (0.48) | CTSL | |
| SCHEMBL20128503 | 0.80 | CSNK2A1 (0.50) | ALOX15ALOX12CSNK2A1FOSTTR | |
| SCHEMBL169779 | 0.79 | PGK1 (0.44) | CSNK2A1HCRTR1HCRTR2SLC1A5 | |
| SCHEMBL10582291 | 0.77 | TTR (0.45) | TTRHCRTR1HCRTR2SLC1A5 | |
| SCHEMBL19725439 | 0.76 | PPARD (0.41) | CSNK2A1HCRTR1HCRTR2SLC1A5 | |
| SCHEMBL12093360 | 0.76 | HCRTR1 (0.43) | HCRTR1HCRTR2SLC1A5 | |
| SCHEMBL25178686 | 0.76 | SLC1A5 (0.40) | HCRTR1HCRTR2SLC1A5 | |
| SCHEMBL3118077 | 0.76 | CSNK2A1 (0.56) | CSNK2A1HCRTR1HCRTR2SLC1A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | ALOX15 4701/4885ALOX12 4667/4885CSNK2A1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.